← MBX Biosciences, Inc. (MBX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MBX Biosciences, Inc. (MBX)
Pharmaceutical Preparations · market cap $2.9B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
MBX Biosciences (MBX) is a small-cap pharmaceutical company with 43 employees and a ~$2.7B market cap, focused on peptide therapeutics. Its lead asset, MBX 2109, is in Phase 2 for hypoparathyroidism via once-weekly subcutaneous injection, with a key data readout estimated around May 2027. The company also has MBX 1416 (imapextide) in Phase 2 for postbariatric hypoglycemia, but faces a critical near-term liquidity problem with only ~6.7 months of cash runway.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-05-27 (est.)Phase 2 · 400 µg of MBX 2109 once-weekly by subcutaneous injectionimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| MBX 2109 | Phase 2 | Hypoparathyroidism |
| 400 µg of MBX 2109 once-weekly by subcutaneous injection | Phase 2 | Hypoparathyroidism |
| MBX 1416 (INN imapextide) | Phase 2 | Postbariatric Hypoglycemia |
Price & technical context
3-month
+2.6%
6-month
+79.4%
12-month
+230.6%
52-wk range
$13.22–$70.70
vs 50-day MA
-6.4%
vs 200-day MA
+36.0%
Realized vol
77.7%
Max drawdown
-77.7%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MBX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.